Director at Organogenesis (NASDAQ: ORGO) purchases 5,000 shares

Rhea-AI Filing Summary

Organogenesis Holdings Inc. director Arthur S. Leibowitz reported an open-market purchase of 5,000 shares of Class A common stock at a price of $2.681 per share on March 9, 2026. Following this transaction, his directly held stake increased to 291,014 shares.

Insider Trade Summary

Net Buyer: 5,000 shares ($13,405)

Net Buy 1 txn

Insider Leibowitz Arthur S

Role Director

Bought 5,000 shs ($13K)

Type	Security	Shares	Price	Value
Purchase	Class A Common Stock	5,000	$2.681	$13K

Holdings After Transaction: Class A Common Stock — 291,014 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leibowitz Arthur S

(Last) (First) (Middle)

C/O ORGANOGENESIS HOLDINGS INC.

85 DAN ROAD

(Street)

CANTON MA 02021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organogenesis Holdings Inc. [ ORGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/09/2026		P		5,000	A	$2.681	291,014	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ William R. Kolb, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Organogenesis (ORGO) report for Arthur S. Leibowitz?

Organogenesis reported that director Arthur S. Leibowitz made an open-market purchase of 5,000 shares of Class A common stock on March 9, 2026. This transaction increased his directly owned stake to 291,014 shares, signaling an additional personal capital commitment.

At what price did the Organogenesis (ORGO) director buy shares?

Arthur S. Leibowitz purchased 5,000 Organogenesis Class A common shares at $2.681 per share. The transaction was classified as an open-market purchase, indicating he bought the stock in the public market rather than through a company grant or option exercise.

How many Organogenesis (ORGO) shares does Arthur S. Leibowitz now hold?

After the reported transaction, Arthur S. Leibowitz directly holds 291,014 shares of Organogenesis Class A common stock. This reflects the addition of 5,000 shares acquired in an open-market purchase, as disclosed in the Form 4 insider trading report filed with regulators.

Was the Organogenesis (ORGO) insider trade a purchase or a sale?

The reported insider trade was a purchase. Director Arthur S. Leibowitz executed an open-market buy of 5,000 shares of Organogenesis Class A common stock at $2.681 per share, increasing his direct ownership to a total of 291,014 shares following the transaction.

What type of security did the Organogenesis (ORGO) insider acquire?

Arthur S. Leibowitz acquired Class A common stock of Organogenesis. The Form 4 specifies the transaction involved 5,000 non-derivative shares purchased in the open market, which raised his directly owned holdings of this common equity class to 291,014 shares in total.